Diabetes, Insufficient blood perfusion, diabetic foot ulcers, cardiovascular disease, peripheral artery disease, stroke, clinical development, formulations of FGF-1, medical indications, active drug development programs, vascular disorders in the brain, vascular disorders feet, vascular disorders heart, Regeneration of new blood vessels via angiogenesis, Regeneration of new blood, angiogenesis, blood vessels in the body, growth factors, stimulate new vessel growth, Insufficient blood perfusion, peripheral artery disease, stroke, therapeutic angiogenesis, unnecessary amputations, Perfusion, cardiovascular health, optimal perfusion. Ischemia, blood flow interrupted, coronary arteries, coronary artery disease, myocardial ischemia, Chest pain, angina, myocardial cells, prolonged ischemia, prolonged ischemia of heart tissue, necrosis, poor circulation, and oxygen-starved hearts, therapeutic angiogenesis, Fibroblast growth factor 1 (FGF-1) potent angiogenic agent, Fibroblast growth factor, growth factors, stimulate angiogenesis, production capillaries, production capillaries arterioles, FGF cell surface receptor, Diabetic foot ulcers, Venous leg ulcers, Stroke, Vascular Dementia, multi-infarct dementia, lack of blood perfusion results, blood brain barrier, IV infusions, Alzheimer’s Disease, degeneration in the microvasculature of the brain, neurofibrillary tangles, Coronary Artery Disease, Dan Montano, Zhittya Regenerative Medicine, life-saving drugs, Jack Jacobs, Ph.D., President and Chief Scientific Officer, Davidson College, Washington University, St. Louis,Viktoriya Tamlenova-Montano, Vice President of Strategic Innovation, heavy industry detailing and construction from Kiev College of Electric Engineering, Construction and Industrial Design Kiev State University of Civil Engineering and Architecture, Kiev State University of Civil Engineering and Architecture, Canada, South East Asia, Latin America, China, India, Korea, Japan, South-East Asia, India, Korea, Japan and Australia, New Zealand, Las Vegas, Las Vegas Nevada, biotechnology, biopharmaceuticals, wound healing biotherapeutics, wound healing
1120 N. Town Center Suite 270, Las Vegas NV 89144 USA

Parkinson’s Disease: Zhittya Genesis Medicine’s research has indicated that Parkinson’s might be a result of reduced blood flow to the brain, especially to the nerves that produce dopamine. ZGM plans to perform clinical trials to see if Parkinson’s patients will improve from administering FGF-1 to the brain. 


To Learn More, Please Watch Our Video

Developing healthier lives for the world​

business

opportunity

vascular

disorders

patients

Insufficient blood perfusion is now recognized as a “common denominator” underlying many deadly and debilitating conditions, including diabetic foot ulcers, cardiovascular disease, peripheral artery disease, stroke, and numerous other disorders.

Zhittya Genesis Medicine, Inc.

Zhittya currently has eight active drug development programs to treat vascular disorders in the brain, feet and heart as well as many others throughout the body.

As we oversee the clinical development of different formulations of FGF-1 for unique medical indications we will work with marketing partners around the world.